Profile data is unavailable for this security.
About the company
Frontier Biotechnologies Inc is a China-based company engaged in research and development, production and sales of innovative drugs. The Company's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The Company conducts its businesses within the China market and to overseas markets.
- Revenue in CNY (TTM)133.67m
- Net income in CNY-279.96m
- Incorporated2013
- Employees395.00
- LocationFrontier Biotechnologies IncHi-Tech Park, Jiangning DistrictNANJING 211199ChinaCHN
- Phone+86 2 569648375
- Fax+86 2 569748373
- Websitehttp://www.frontierbiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 732.68m | 166.02m | 2.72bn | 738.00 | 16.40 | 2.19 | -- | 3.72 | 0.5072 | 0.5072 | 2.24 | 3.80 | 0.4013 | 2.01 | 17.68 | 992,793.70 | 9.07 | 12.01 | 11.17 | 14.75 | 66.13 | 69.79 | 22.60 | 22.84 | 1.01 | -- | 0.1998 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Frontier Biotechnologies Inc | 133.67m | -279.96m | 2.90bn | 395.00 | -- | 2.53 | -- | 21.72 | -0.7474 | -0.7474 | 0.3569 | 3.07 | 0.0636 | 1.61 | 2.72 | 338,416.90 | -13.31 | -14.05 | -16.40 | -15.78 | 33.62 | 2.35 | -209.43 | -450.08 | 2.02 | -- | 0.2808 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.24bn | 20.30m | 3.07bn | 2.35k | 161.26 | 1.41 | -- | 2.48 | 0.087 | 0.087 | 5.70 | 9.92 | 0.267 | 1.18 | 4.91 | 525,730.80 | 0.5164 | 4.94 | 0.7951 | 7.83 | 29.01 | 35.39 | 1.93 | 13.71 | 0.7203 | 4.44 | 0.4199 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
| Jiangsu Lianhuan Pharmaceutical Co. Ltd | 2.34bn | 138.87m | 3.09bn | 1.30k | 22.22 | 2.20 | -- | 1.32 | 0.4865 | 0.4865 | 8.18 | 4.92 | 0.8003 | 3.34 | 4.76 | 1,801,909.00 | 5.42 | 5.93 | 11.26 | 11.25 | 49.14 | 53.26 | 6.78 | 7.82 | 0.7061 | 6.61 | 0.3593 | 30.64 | 11.20 | 16.36 | -4.50 | 12.91 | 9.35 | 13.97 |
Data as of Sep 13 2024. Currency figures normalised to Frontier Biotechnologies Inc's reporting currency: Chinese Yuan Renminbi CNY
5.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nuode Asset Management Co., Ltd.as of 21 Mar 2023 | 4.81m | 2.34% |
| UBS Asset Management Switzerland AGas of 21 Mar 2023 | 4.63m | 2.25% |
| AEON Insurance Asset Management Co., Ltd.as of 21 Mar 2023 | 740.19k | 0.36% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 676.59k | 0.33% |
| Chang Xin Asset Management Co., Ltd.as of 30 Jun 2024 | 270.10k | 0.13% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 2024 | 213.75k | 0.10% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 207.33k | 0.10% |
| BOSC Asset Management Co. Ltd.as of 30 Jun 2024 | 104.86k | 0.05% |
| Bohai Huijin Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 70.40k | 0.03% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 50.70k | 0.03% |
More ▼
Data from 09 Jun 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
